This invention discloses a pharmaceutical composition for alleviating sotorasidib-induced
intestinal injury and its uses, belonging to the field of
pharmaceutical technology. This invention proposes an intervention strategy to prevent and / or alleviate sotorasidib-induced
intestinal injury by activating the cAMP signaling pathway. The cAMP signaling pathway activator can restore PKA activity and / or
CREB phosphorylation levels, reduce sotorasidib-induced intestinal epithelial
cell apoptosis, improve
cell proliferation, and alleviate intestinal barrier damage. This invention also provides a combination of the cAMP signaling pathway activator and sotorasidib for the preparation of antitumor drugs.
Cell model
verification showed that the combined strategy did not significantly weaken the antitumor effect of sotorasidib, suggesting that this combined strategy has the potential for application as an
adjuvant protective measure.